- call +1-201-465-4211
- email sales@mrinsights.biz
Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by damage to the dopaminergic neurons located in various parts of the brain, including the substantia nigra.
Scope of the Report:
This report focuses on the Parkinson's Disease (PD) Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
The emergence of gene therapy to reverse the progression of PD is one of the key trends that will gain traction in the market for parkinsons drugs throughout the estimated period.
The worldwide market for Parkinson's Disease (PD) Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new study.
Market Segment by Manufacturers, this report covers
Boehringer Ingelheim
GlaxoSmithKline
Novartis
Teva Pharmaceutical Industries
AbbVie
Abital Pharma
Addex Therapeutics
Biogen
Eisai
Eli Lilly
F. Hoffmann-La Roche
H. Lundbeck
Impax Laboratories
Kyowa Hakko Kirin
Otsuka Pharmaceutical
Pfizer
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Dopamine Agonist
Monoamine Oxidase Inhibitors
Acetylcholinesterase Inhibitors
Glutamate Inhibitors
Market Segment by Applications, can be divided into
Hospital
Family
There are 15 Chapters to deeply display the global Parkinson's Disease (PD) Drugs market.
Chapter 1, to describe Parkinson's Disease (PD) Drugs Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Parkinson's Disease (PD) Drugs, with sales, revenue, and price of Parkinson's Disease (PD) Drugs, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Parkinson's Disease (PD) Drugs, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Parkinson's Disease (PD) Drugs market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Parkinson's Disease (PD) Drugs sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Market Overview
1.1 Parkinson's Disease (PD) Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Dopamine Agonist
1.2.2 Monoamine Oxidase Inhibitors
1.2.3 Acetylcholinesterase Inhibitors
1.2.4 Glutamate Inhibitors
1.3 Market Analysis by Applications
1.3.1 Hospital
1.3.2 Family
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Boehringer Ingelheim
2.1.1 Business Overview
2.1.2 Parkinson's Disease (PD) Drugs Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Boehringer Ingelheim Parkinson's Disease (PD) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 GlaxoSmithKline
2.2.1 Business Overview
2.2.2 Parkinson's Disease (PD) Drugs Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 GlaxoSmithKline Parkinson's Disease (PD) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 Novartis
2.3.1 Business Overview
2.3.2 Parkinson's Disease (PD) Drugs Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Novartis Parkinson's Disease (PD) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 Teva Pharmaceutical Industries
2.4.1 Business Overview
2.4.2 Parkinson's Disease (PD) Drugs Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Teva Pharmaceutical Industries Parkinson's Disease (PD) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 AbbVie
2.5.1 Business Overview
2.5.2 Parkinson's Disease (PD) Drugs Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 AbbVie Parkinson's Disease (PD) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6 Abital Pharma
2.6.1 Business Overview
2.6.2 Parkinson's Disease (PD) Drugs Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Abital Pharma Parkinson's Disease (PD) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7 Addex Therapeutics
2.7.1 Business Overview
2.7.2 Parkinson's Disease (PD) Drugs Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Addex Therapeutics Parkinson's Disease (PD) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8 Biogen
2.8.1 Business Overview
2.8.2 Parkinson's Disease (PD) Drugs Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Biogen Parkinson's Disease (PD) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.9 Eisai
2.9.1 Business Overview
2.9.2 Parkinson's Disease (PD) Drugs Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Eisai Parkinson's Disease (PD) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.10 Eli Lilly
2.10.1 Business Overview
2.10.2 Parkinson's Disease (PD) Drugs Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Eli Lilly Parkinson's Disease (PD) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.11 F. Hoffmann-La Roche
2.11.1 Business Overview
2.11.2 Parkinson's Disease (PD) Drugs Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 F. Hoffmann-La Roche Parkinson's Disease (PD) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.12 H. Lundbeck
2.12.1 Business Overview
2.12.2 Parkinson's Disease (PD) Drugs Type and Applications
2.12.2.1 Product A
2.12.2.2 Product B
2.12.3 H. Lundbeck Parkinson's Disease (PD) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.13 Impax Laboratories
2.13.1 Business Overview
2.13.2 Parkinson's Disease (PD) Drugs Type and Applications
2.13.2.1 Product A
2.13.2.2 Product B
2.13.3 Impax Laboratories Parkinson's Disease (PD) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.14 Kyowa Hakko Kirin
2.14.1 Business Overview
2.14.2 Parkinson's Disease (PD) Drugs Type and Applications
2.14.2.1 Product A
2.14.2.2 Product B
2.14.3 Kyowa Hakko Kirin Parkinson's Disease (PD) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.15 Otsuka Pharmaceutical
2.15.1 Business Overview
2.15.2 Parkinson's Disease (PD) Drugs Type and Applications
2.15.2.1 Product A
2.15.2.2 Product B
2.15.3 Otsuka Pharmaceutical Parkinson's Disease (PD) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.16 Pfizer
2.16.1 Business Overview
2.16.2 Parkinson's Disease (PD) Drugs Type and Applications
2.16.2.1 Product A
2.16.2.2 Product B
2.16.3 Pfizer Parkinson's Disease (PD) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 Global Parkinson's Disease (PD) Drugs Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)
3.1 Global Parkinson's Disease (PD) Drugs Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Parkinson's Disease (PD) Drugs Revenue and Market Share by Manufacturer (2016-2017)
3.3 Market Concentration Rate
3.3.1 Top 3 Parkinson's Disease (PD) Drugs Manufacturer Market Share in 2017
3.3.2 Top 6 Parkinson's Disease (PD) Drugs Manufacturer Market Share in 2017
3.4 Market Competition Trend
4 Global Parkinson's Disease (PD) Drugs Market Analysis by Regions
4.1 Global Parkinson's Disease (PD) Drugs Sales, Revenue and Market Share by Regions
4.1.1 Global Parkinson's Disease (PD) Drugs Sales and Market Share by Regions (2013-2018)
4.1.2 Global Parkinson's Disease (PD) Drugs Revenue and Market Share by Regions (2013-2018)
4.2 North America Parkinson's Disease (PD) Drugs Sales and Growth Rate (2013-2018)
4.3 Europe Parkinson's Disease (PD) Drugs Sales and Growth Rate (2013-2018)
4.4 Asia-Pacific Parkinson's Disease (PD) Drugs Sales and Growth Rate (2013-2018)
4.5 South America Parkinson's Disease (PD) Drugs Sales and Growth Rate (2013-2018)
4.6 Middle East and Africa Parkinson's Disease (PD) Drugs Sales and Growth Rate (2013-2018)
5 North America Parkinson's Disease (PD) Drugs by Countries
5.1 North America Parkinson's Disease (PD) Drugs Sales, Revenue and Market Share by Countries
5.1.1 North America Parkinson's Disease (PD) Drugs Sales and Market Share by Countries (2013-2018)
5.1.2 North America Parkinson's Disease (PD) Drugs Revenue and Market Share by Countries (2013-2018)
5.2 United States Parkinson's Disease (PD) Drugs Sales and Growth Rate (2013-2018)
5.3 Canada Parkinson's Disease (PD) Drugs Sales and Growth Rate (2013-2018)
5.4 Mexico Parkinson's Disease (PD) Drugs Sales and Growth Rate (2013-2018)
6 Europe Parkinson's Disease (PD) Drugs by Countries
6.1 Europe Parkinson's Disease (PD) Drugs Sales, Revenue and Market Share by Countries
6.1.1 Europe Parkinson's Disease (PD) Drugs Sales and Market Share by Countries (2013-2018)
6.1.2 Europe Parkinson's Disease (PD) Drugs Revenue and Market Share by Countries (2013-2018)
6.2 Germany Parkinson's Disease (PD) Drugs Sales and Growth Rate (2013-2018)
6.3 UK Parkinson's Disease (PD) Drugs Sales and Growth Rate (2013-2018)
6.4 France Parkinson's Disease (PD) Drugs Sales and Growth Rate (2013-2018)
6.5 Russia Parkinson's Disease (PD) Drugs Sales and Growth Rate (2013-2018)
6.6 Italy Parkinson's Disease (PD) Drugs Sales and Growth Rate (2013-2018)
7 Asia-Pacific Parkinson's Disease (PD) Drugs by Countries
7.1 Asia-Pacific Parkinson's Disease (PD) Drugs Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Parkinson's Disease (PD) Drugs Sales and Market Share by Countries (2013-2018)
7.1.2 Asia-Pacific Parkinson's Disease (PD) Drugs Revenue and Market Share by Countries (2013-2018)
7.2 China Parkinson's Disease (PD) Drugs Sales and Growth Rate (2013-2018)
7.3 Japan Parkinson's Disease (PD) Drugs Sales and Growth Rate (2013-2018)
7.4 Korea Parkinson's Disease (PD) Drugs Sales and Growth Rate (2013-2018)
7.5 India Parkinson's Disease (PD) Drugs Sales and Growth Rate (2013-2018)
7.6 Southeast Asia Parkinson's Disease (PD) Drugs Sales and Growth Rate (2013-2018)
8 South America Parkinson's Disease (PD) Drugs by Countries
8.1 South America Parkinson's Disease (PD) Drugs Sales, Revenue and Market Share by Countries
8.1.1 South America Parkinson's Disease (PD) Drugs Sales and Market Share by Countries (2013-2018)
8.1.2 South America Parkinson's Disease (PD) Drugs Revenue and Market Share by Countries (2013-2018)
8.2 Brazil Parkinson's Disease (PD) Drugs Sales and Growth Rate (2013-2018)
8.3 Argentina Parkinson's Disease (PD) Drugs Sales and Growth Rate (2013-2018)
8.4 Colombia Parkinson's Disease (PD) Drugs Sales and Growth Rate (2013-2018)
9 Middle East and Africa Parkinson's Disease (PD) Drugs by Countries
9.1 Middle East and Africa Parkinson's Disease (PD) Drugs Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Parkinson's Disease (PD) Drugs Sales and Market Share by Countries (2013-2018)
9.1.2 Middle East and Africa Parkinson's Disease (PD) Drugs Revenue and Market Share by Countries (2013-2018)
9.2 Saudi Arabia Parkinson's Disease (PD) Drugs Sales and Growth Rate (2013-2018)
9.3 UAE Parkinson's Disease (PD) Drugs Sales and Growth Rate (2013-2018)
9.4 Egypt Parkinson's Disease (PD) Drugs Sales and Growth Rate (2013-2018)
9.5 Nigeria Parkinson's Disease (PD) Drugs Sales and Growth Rate (2013-2018)
9.6 South Africa Parkinson's Disease (PD) Drugs Sales and Growth Rate (2013-2018)
10 Global Parkinson's Disease (PD) Drugs Market Segment by Type
10.1 Global Parkinson's Disease (PD) Drugs Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global Parkinson's Disease (PD) Drugs Sales and Market Share by Type (2013-2018)
10.1.2 Global Parkinson's Disease (PD) Drugs Revenue and Market Share by Type (2013-2018)
10.2 Dopamine Agonist Sales Growth and Price
10.2.1 Global Dopamine Agonist Sales Growth (2013-2018)
10.2.2 Global Dopamine Agonist Price (2013-2018)
10.3 Monoamine Oxidase Inhibitors Sales Growth and Price
10.3.1 Global Monoamine Oxidase Inhibitors Sales Growth (2013-2018)
10.3.2 Global Monoamine Oxidase Inhibitors Price (2013-2018)
10.4 Acetylcholinesterase Inhibitors Sales Growth and Price
10.4.1 Global Acetylcholinesterase Inhibitors Sales Growth (2013-2018)
10.4.2 Global Acetylcholinesterase Inhibitors Price (2013-2018)
10.5 Glutamate Inhibitors Sales Growth and Price
10.5.1 Global Glutamate Inhibitors Sales Growth (2013-2018)
10.5.2 Global Glutamate Inhibitors Price (2013-2018)
11 Global Parkinson's Disease (PD) Drugs Market Segment by Application
11.1 Global Parkinson's Disease (PD) Drugs Sales Market Share by Application (2013-2018)
11.2 Hospital Sales Growth (2013-2018)
11.3 Family Sales Growth (2013-2018)
12 Parkinson's Disease (PD) Drugs Market Forecast (2018-2023)
12.1 Global Parkinson's Disease (PD) Drugs Sales, Revenue and Growth Rate (2018-2023)
12.2 Parkinson's Disease (PD) Drugs Market Forecast by Regions (2018-2023)
12.2.1 North America Parkinson's Disease (PD) Drugs Market Forecast (2018-2023)
12.2.2 Europe Parkinson's Disease (PD) Drugs Market Forecast (2018-2023)
12.2.3 Asia-Pacific Parkinson's Disease (PD) Drugs Market Forecast (2018-2023)
12.2.4 South America Parkinson's Disease (PD) Drugs Market Forecast (2018-2023)
12.2.5 Middle East and Africa Parkinson's Disease (PD) Drugs Market Forecast (2018-2023)
12.3 Parkinson's Disease (PD) Drugs Market Forecast by Type (2018-2023)
12.3.1 Global Parkinson's Disease (PD) Drugs Sales Forecast by Type (2018-2023)
12.3.2 Global Parkinson's Disease (PD) Drugs Market Share Forecast by Type (2018-2023)
12.4 Parkinson's Disease (PD) Drugs Market Forecast by Application (2018-2023)
12.4.1 Global Parkinson's Disease (PD) Drugs Sales Forecast by Application (2018-2023)
12.4.2 Global Parkinson's Disease (PD) Drugs Market Share Forecast by Application (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
List of Tables and Figures
Figure Parkinson's Disease (PD) Drugs Picture
Table Product Specifications of Parkinson's Disease (PD) Drugs
Figure Global Sales Market Share of Parkinson's Disease (PD) Dr
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
